William Blair Downgrades Splunk
William Blair has downgraded its outlook for Splunk to Market Perform.
By 247patrick
· 11:48pm ET Archive
Day: September 21, 2023
By 247patrick
· 11:48pm ET 11:14pm ET
Investing
Buy the Dip? 2 Top Ranked Tech Stocks Pulling Back Now
Why the current scenario is ripe with opportunities, particularly within the resilient tech sector.
247patrick 11:05pm ET
Investing
3 Top-Ranked Tech Stocks to Buy for High Growth
These three stocks boast big growth trajectories and sport improved earnings outlooks.
247patrick 11:05pm ET
Investing
Buy These Momentum Stocks as Fed Leaves Rates Unchanged but Markets Fall
These stocks serve as buy-the-dip candidates or have the potential to propel past temporary headwinds.
247patrick All Day: September 21, 2023 Articles
Newest first
Over 20 ESG Funds Shut Down in 2023 Amid Fading Interest
More than 20 environmental, social, and corporate governance (ESG) funds closed in 2023 due to poor performance and amid greenwashing allegations.
Fed Dampens Wall Street Sentiments: 5 Safe Stock Picks
These stocks have strong potential for the rest of 2023 and have seen positive earnings estimate revisions in the last 60 days.
Grab These 5 Flourishing Giants to Strengthen Your Portfolio
These five large-cap stocks have provided solid returns in the past month and have strong long-term potential.
Fed Signals High Rates for Long Term: What It Means for Banks
Banks are likely to continue facing a tough operating backdrop into the next year.
4 Solid Bets in the Promising Retail-Apparel & Shoes Industry
Retailers have been focusing on the superior product strategy, the advancement of omnichannel capabilities, prudent capital investments and greater customer reach.
5 Stocks to Gain From Fed’s Decision to Pause Rate Hikes
Why investing in consumer discretionary stocks like these would be a wise decision now.
Zacks Industry Outlook Highlights General Electric, 3M Company and ITT.
Easing supply chains and cost-control measures are expected to aid the bottom lines of these companies.
Biotech Stock Roundup: GSK’s Drug Approval, MRNA’s Vaccine News, PTCT & SPRY Down
It was a busy week for the biotech sector, with a lot of important regulatory and pipeline updates.